Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Kee-Hyun | - |
dc.date.accessioned | 2024-01-20T12:00:50Z | - |
dc.date.available | 2024-01-20T12:00:50Z | - |
dc.date.created | 2021-09-05 | - |
dc.date.issued | 2013-08 | - |
dc.identifier.issn | 1746-0441 | - |
dc.identifier.uri | https://pubs.kist.re.kr/handle/201004/127816 | - |
dc.description.abstract | Introduction: Neuronal T-type calcium channels (T-type channels) are expressed throughout the central nervous system (CNS), regulating neuronal excitability. T-type channels in the CNS are involved in various neurophysiological and pathophysiological states, and thus have become a promising therapeutic target. Areas covered: This article discusses T-type channel-related CNS disorders such as epilepsy, neuropathic pain, insomnia and tremor disorders including Parkinson's disease. In addition, the article reviews T-type channel inhibitors showing efficacy in animal models in such CNS disorders, with a focus on classical T-type channel inhibitors with limited specificity for T-type channels as well as novel inhibitors with high specificity. Furthermore, the article also presents and discusses the next generation of T-type channel inhibitor discovery, virtual as well as screening and high-throughput screening techniques. Expert opinion: Although T-type channel-related CNS disorders seem to be diverse, it converges into the one major cause - abnormal hyperactivity of neurons. T-type channel-specific inhibitors could thus be commonly applied for the treatment of such CNS disorders regardless of the complexity of individual disorder. Structural information of inhibitor-binding sites would facilitate the discovery of the next generation of T-type channel-specific inhibitors by stimulating structure-based rational drug designs. | - |
dc.language | English | - |
dc.publisher | INFORMA HEALTHCARE | - |
dc.subject | RAT SENSORY NEURONS | - |
dc.subject | 5-ALPHA-REDUCED NEUROACTIVE STEROIDS | - |
dc.subject | CHILDHOOD ABSENCE EPILEPSY | - |
dc.subject | CA2+ CHANNELS | - |
dc.subject | IN-VITRO | - |
dc.subject | THALAMIC NEURONS | - |
dc.subject | ESSENTIAL TREMOR | - |
dc.subject | UP-REGULATION | - |
dc.subject | PARKINSONS-DISEASE | - |
dc.subject | NEUROPATHIC PAIN | - |
dc.title | The design and discovery of T-type calcium channel inhibitors for the treatment of central nervous system disorders | - |
dc.type | Article | - |
dc.identifier.doi | 10.1517/17460441.2013.796926 | - |
dc.description.journalClass | 1 | - |
dc.identifier.bibliographicCitation | EXPERT OPINION ON DRUG DISCOVERY, v.8, no.8, pp.919 - 931 | - |
dc.citation.title | EXPERT OPINION ON DRUG DISCOVERY | - |
dc.citation.volume | 8 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 919 | - |
dc.citation.endPage | 931 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.identifier.wosid | 000322078000002 | - |
dc.identifier.scopusid | 2-s2.0-84880752150 | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.type.docType | Review | - |
dc.subject.keywordPlus | RAT SENSORY NEURONS | - |
dc.subject.keywordPlus | 5-ALPHA-REDUCED NEUROACTIVE STEROIDS | - |
dc.subject.keywordPlus | CHILDHOOD ABSENCE EPILEPSY | - |
dc.subject.keywordPlus | CA2+ CHANNELS | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | THALAMIC NEURONS | - |
dc.subject.keywordPlus | ESSENTIAL TREMOR | - |
dc.subject.keywordPlus | UP-REGULATION | - |
dc.subject.keywordPlus | PARKINSONS-DISEASE | - |
dc.subject.keywordPlus | NEUROPATHIC PAIN | - |
dc.subject.keywordAuthor | calcium channel inhibitors | - |
dc.subject.keywordAuthor | central nervous system disorders | - |
dc.subject.keywordAuthor | rational drug design | - |
dc.subject.keywordAuthor | T-type calcium channels | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.